Feed CYYNF
CY

Cynata Therapeutics Limited

CYYNF · OTC

$0.00 +0.00% (+$0.00)
Market Cap $2.92M
P/E Ratio -
Div. Yield -
ROE 133.81%
Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Weak
1/9
Valuation
94 /100
Cheap
P/B 0.49x
P/S 1.55x
P/FFO N/A
Growth
0 /100
Declining
Book val. growth 37.03%
Rev. growth 37.63%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 498.14%
Op. margin 430.95%
FCF margin 465.24%
Quality
3 /100
Poor
ROE 133.81%
ROA 130.46%
Asset turnover 0.26x
Debt
100 /100
Low
Current ratio 4.40x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
19 /100
Unstable
Rev. volatility 59.34%
EPS volatility 110.20%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CYYNF
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Kilian Kelly

Employees

2

Headquarters

Cremorne

Upcoming events

25 FEB

Earnings

Upcoming earnings report

149d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.